AbbVie stock rises after strong quarterly earnings and upgraded 2026 guidance

13 articles · Updated · Barron's · Apr 29

AbbVie reported Q1 adjusted earnings of $2.65 per share and $15 billion in revenue, both exceeding analyst expectations.
The company raised its 2026 adjusted earnings guidance to $14.08–$14.28 per share, up from its previous forecast, prompting shares to jump 2.5% in premarket trading.
Growth in immunology and neuroscience portfolios, including Skyrizi and Rinvoq, offset a 39% decline in Humira sales, reversing some of AbbVie's earlier 2026 stock losses.

AbbVie's revenue is soaring, so why did its net profit plummet?

Can two blockbuster drugs truly replace the long-reigning Humira empire?

Is AbbVie's high stock price a sign of strength or a bubble?

How will AbbVie's pricing agreement with the government impact drug access?

Beyond immunology, is AbbVie's new obesity drug its next big bet?

With Humira's patent gone, will patients finally see lower drug prices?